Constitutive androstane receptor (CAR) is a xenobiotic-responsive nuclear receptor that is highly expressed in the liver. CAR activation induces hepatocyte proliferation and hepatocarcinogenesis in rodents, but the mechanisms remain unclear. In this study, we investigated the association of CAR-dependent cell proliferation with Yes-associated protein (YAP), which is a transcriptional cofactor controlling organ size and cell growth through the interaction with various transcriptional factors including TEA domain family member (TEAD). In mouse livers, 1,4-bis-(2-[3,5-dichloropyridyloxy])benzene (TCPOBOP) (a mouse CAR [mCAR] activator) treatment increased the nuclear YAP accumulation and mRNA levels of YAP target genes as well as cell-cycle related genes along with liver hypertrophy and verteporfin (an inhibitor of YAP/TEAD interaction) cotreatment tended to attenuate them. Furthermore, in cell-based reporter gene assays, CAR activation enhanced the YAP/TEAD-dependent transcription. To investigate the role of YAP/TEAD activation in the CAR-dependent hepatocyte proliferation, we sought to establish an in vitro system completely reproducing CAR-dependent cell proliferation. Since CAR was only slightly expressed in cultured mouse primary hepatocytes compared with mouse livers and no proliferation was observed after treatment with TCPOBOP, we overexpressed CAR using mCAR expressing adenovirus (Ad-mCAR-V5) in mouse primary hepatocytes. Ad-mCAR-V5 infection and TCPOBOP treatment induced hepatocyte proliferation. Similar results were obtained with immortalized normal mouse hepatocytes as well. In the established in vitro system, CARdependent proliferation was strongly inhibited by Yap knockdown and completely abolished by verteporfin treatment. Our present results obtained in in vivo and in vitro experiments suggest that YAP/TEAD activation plays key roles in CARdependent proliferation of murine hepatocytes.
in rodents. For instance, phenobarbital, a typical nonligand CAR activator, is a nongenotoxic hepatocarcinogen, i.e., liver tumor promoter. Its prolonged exposure induces liver tumor formation in rodents (Wei et al., 2000; Williams et al., 1996) , and phenobarbital-dependent hepatocarcinogenesis was not observed in Car-null mice . We recently reported that perfluorocarboxylic acid, a hepatocarcinogenic environmental pollutant (Hernandez et al., 2009) , induces liver hypertrophy through CAR activation (Abe et al., 2017) . CAR activation induced the expressions of the oncogene Myc and its target Foxm1 (Blanco-Bose et al., 2008; Osabe et al., 2008) and increased the mRNA levels of Gadd45b, which encodes a modulator of p53 tumor suppressor protein, and Ccnd1, which accelerates the entry of quiescent hepatocyte into G1/S-phase (Ledda-Columbano et al., 2000) , suggesting their roles in CARmediated hepatocyte hyperplasia. However, the mechanisms underlying the CAR-mediated hepatocyte proliferation and hepatocarcinogenesis have not been fully elucidated, although the role of CAR in the chemical-induced hepatocarcinogenesis in rodents has been well established. One of the reasons for this is the lack of an in vitro system(s) reproducing CAR-dependent cell proliferation, as no cell lines expressing CAR as strongly as in intact hepatocytes have been reported.
Yes-associated protein (YAP) is a key transcriptional cofactor for liver hypertrophy and carcinogenesis . Its transcriptional activity is regulated by the Hippo pathway, a signal transduction pathway controlling cell and organ size (Halder et al., 2011) . In mammals, the pathway is composed of mammalian Ste20-like kinases MST1/2 and large tumor suppressor kinases LATS1/2, which phosphorylate YAP to keep it in the cytoplasm in a transcriptionally inactive form (Lee et al., 2007; Lin et al., 2013) . The Hippo pathway is strongly activated in normal livers (Song et al., 2010; Zhou et al., 2009 ), but often disrupted in liver cancer and other carcinomas Zender et al., 2006) , where the amount of dephosphorylated and nuclear (i.e., active) YAP is increased. In the nucleus, YAP interacts with TEA domain family members (TEADs) and other transcription factors, such as peroxisome proliferator-activated receptor c (PPARc), SMADs and p73, as either transcriptional coactivator and corepressor (Guo et al., 2015) . TEAD-mediated gene transcription is involved in cell proliferation and antiapoptosis. Intriguingly, a recent report showed that the treatment of mice with a mouse CAR (mCAR) activator promoted YAP nuclear translocation in the liver (Kowalik et al., 2011) . However, the causal relationship between YAP activation and CARdependent hepatocyte proliferation or liver hypertrophy remains to be elucidated.
Based on these previous findings, we have hypothesized that YAP plays a role in the CAR-dependent hepatocyte proliferation. To investigate this hypothesis, we established an in vitro system where CAR-dependent hepatocyte proliferation can be observed, and then evaluated the role of YAP in the CARmediated proliferation of murine hepatocytes.
MATERIALS AND METHODS
Materials. 1,4-bis-(2-[3,5-Dichloropyridyloxy])benzene (TCPOBOP), collagenase (type IV) and pregnenolone 16a-carbonitrile (PCN) were obtained from Sigma-Aldrich (St Louis, Missouri). Verteporfin was purchased from AdooQ Biosciences (Irvine, California). Oligonucleotides were synthesized by Fasmac (Atsugi, Japan). Anti-YAP and anti-lamin B antibodies were obtained from Santa Cruz Biotechnology (Santa Cruz, California).
ON-TARGETplus Non-targeting Pool and ON-TARGETplus SMART Pool-mYAP were purchased from GE Healthcare Dharmacon (Lafayette, Connecticut). All other chemicals were of the highest grade available from Wako Pure Chemical Industries (Osaka, Japan), Thermo Fisher Scientific (Waltham, Massachusetts) or Sigma-Aldrich.
Animals. Male C57BL/6 wild-type (Charles River Laboratories Japan, Yokohama, Japan) mice were maintained in a temperature and light controlled environment (24 C, 12-h light/dark cycle). In Figure 1 , mice (around 8 weeks of age) were intraperitoneally treated with vehicle (corn oil, 20 ml/kg) or TCPOBOP (3 mg/kg) once a day for 3 days, and sacrificed by cervical dislocation. Their livers were collected 24 h after the last administration. In Figure 2 , mice were intrapritoneally treated with vehicle (corn oil, 20 ml/kg), TCPOBOP (3 mg/kg) and/or verteporfin (100 mg/kg) and sacrificed by cervical dislocation as indicated in Figure 2A . All animal experiments were performed according to the guidelines for animal experiments of University of Shizuoka.
Cell culture and adenovirus infection. Mouse primary hepatocytes were isolated from the liver by the 2-step collagenase perfusion method described in Seglen's report (Seglen, 1976) with some modifications (Abe et al., 2017 Shizu et al. (2016) . AML12 cells were precultured for 24 h, infected with adenovirus and treated with vehicle (0.1% DMSO) or 0.25 mM TCPOBOP under the serum-free condition. Forty-eight hours later, the cells were retreated with the vehicle or TCPOBOP in fresh serum-free medium. The AML12 cell line was authenticated by ATCC using morphology, karyotyping, and PCR-based approaches and the cells were used within a month after resuscitation.
Small interfering RNA transfection. AML12 cells were reversetransfected with 10 nM ON-TARGETplus Non-targeting Pool or ON-TARGETplus SMART Pool-mYAP (mYAP-siRNA) using Lipofectamine RNAiMAX (Thermo Fisher Scientific). Twentyfour hours later, the cells were infected with adenovirus and treated with vehicle (0.1% DMSO) or 0.25 mM TCPOBOP as described earlier.
Western blot analyses. Liver nuclear extracts were prepared by using NE-PER Nuclear and Cytoplasmic Extraction Reagents (Thermo Fisher Scientific) and subjected to Western blot analyses as described previously in Inoue et al. (2011) . Anti-YAP and anti-lamin B antibodies were used as primary antibodies.
Plasmids and adenoviruses. mCAR-pcDNA3.1 and LacZexpressing adenovirus (Ad-LacZ) preparation has been described previously (Imai et al., 2013; Aoyama et al., 2009 ). To prepare V5-tagged mCAR-expressing adenovirus (Ad-mCAR-V5), mCAR cDNA was subcloned into pShuttle-CMV from mCAR-pcDNA3.1 using KOD-Plus-Neo (Toyobo, Osaka, Japan) with specific primers (Supplementary Table 1 ). V5-tag was inserted at the C terminus of mCAR in pShuttle-CMV using specific primers and the KOD-Plus-Mutagenesis kit (Toyobo) (Supplementary Table 1 ). The integration of p-Shuttle-CMV and pAdEasy-1, the generation of the final adenovirus and the measurement of the titer were described previously (Shizu et al., 2016) . mYAP cDNA was amplified by PCR and inserted into the pTargeT plasmid vector (Promega, Madison, Wisconsin). The dominant active form of mYAP (mYAP-5SA), in which all 5 phosphorylation sites (S46, S94, S112, S149, S382) targeted by the Hippo pathway were mutated to alanine using the KOD-Plus-Mutagenesis kit with specific primers (Supplementary Table 1 ). pTA-Luc and TEAD-pTA reporter plasmids were purchased from Signosis (Sunnyvale, California). Reporter gene assay. AML12 cells were reverse-transfected with pTA-Luc or TEAD-pTA and expression plasmids for 24 h and treated with vehicle (0.1% DMSO) or 0.25 mM TCPOBOP for an additional 24 h under serum-free conditions. The reporter activities were measured using a Dual-Glo Luciferase Assay System (Promega).
Immunohistochemistry. Livers were fixed in 10% neutral buffered formalin (Wako Pure Chemical Industries). Sections were stained with anti-Ki-67 or anti-YAP antibody and counterstained with hematoxylin using the standard procedures by Morphotechnology (Sapporo, Japan). Image capture and acquisition were carried out as described previously (Shizu et al., 2016) .
Quantitative reverse transcription-PCR. Total RNA preparation and cDNA synthesis were carried out as described previously in Shizu et al. (2016) . quantitative reverse transcription-PCR (qRT-PCR) was carried out using GoTaq qPCR Master Mix (Promega) and specific primer sets for each target gene (Supplementary Table 2 ). These mRNA levels were normalized to Actb (b-actin) mRNA levels.
Statistical analysis. Statistical analyses were performed using the JMP Pro 12 software program (SAS Institute, Cary, North Carolina). All data are provided as the mean 6 SD. The significance of differences between the control and treated groups was assessed by Student's t test or a 1-way analysis of variance followed by Dunnett's test or Tukey-Kramer test.
RESULTS

Role of Yap/TEAD Complex in CAR-Dependent Liver Hypertrophy and Hepatocyte Proliferation in Mice
To investigate whether or not CAR activation could promote YAP nuclear translocation (i.e., activation) in mouse livers, mice were treated with vehicle or TCPOBOP, an mCAR activator. The liver-to-body weight ratio and hepatic mRNA levels of the CAR target genes Cyp2b10 and Cyp2c55 were increased by TCPOBOP treatment, as expected (Figs. 1A and 1C) . In addition, TCPOBOP treatment remarkably increased the number of Ki-67-positive hepatocytes ( Figure 1B) as well as the mRNA levels of cell proliferation marker genes, such as Ccna2, Ccnb1, Mcm2, and Foxm1 ( Figure 1C ) in the liver. A Western blot analysis of liver nuclear extracts using anti-YAP antibody showed that the nuclear YAP protein levels were remarkably increased by TCPOBOP treatment ( Figure 1D ). The nuclear accumulation of YAP by TCPOBOP treatment was confirmed by immunohistochemical analyses of liver sections ( Figure 1E ). Consistently, TCPOBOP treatment significantly increased the hepatic mRNA level of YAP target genes Birc5 and Myc and tended to increase those of Ankrd1 ( Figure 1C ). Next, mice were treated with TCPOBOP with or without verteporfin, an inhibitor of YAP/TEAD interaction (Liu-Chittenden et al., 2012). As expected, TCPOBOP treatment induced liver hypertrophy and increased the mRNA levels of cell-cycle related as well as YAP-target genes in the liver (Figure 2 ). Verteporfin treatment prevented the TCPOBOPinduced liver hypertrophy and tended to attenuate the increase in the mRNA levels of YAP target genes. such as Ankrd1 and Birc5, and those related to hepatocyte proliferation, such as Ccna2, Ccnb1, and Mcm2 (Figure 2) . Intriguingly, the induced expression of the CAR target genes Cyp2b10 and Cyp2c55 were also suppressed by verteporfin treatment (Figure 2 ). These results suggest the presence of functional interaction between YAP/TEAD activation and CAR-dependent hepatocyte proliferation in mice.
The Crosstalk between CAR and Yap in Gene Transcription
To investigate the crosstalk between CAR and YAP/TEAD signals in gene transcription, reporter gene assays with TEAD-responsive reporter plasmid (TEAD-pTA) were performed. Since it is reported that activated LATS1/2 phosphorylates at least 5 serine residues of YAP, we used both wild-type and the dominant active form of mYAP (mYAP-5SA), in which all 5 phosphorylation sites (S46, S94, S112, S149, and S382) for LATS1/2 are mutated to alanine (Yabuta et al., 2013; Zhao et al., 2007) . In AML12 cells, the TEAD-dependent reporter activities were increased by the ectopic expression of wild-type mYAP (mYAP-WT) or mYAP-5SA in a dose-dependent manner, and the increase was more obvious with mYAP-5SA, as expected ( Figure 3A) . We then investigated whether or not mCAR activation could affect the YAP/TEAD-dependent transcription. As shown in Figure 3B , mYAP-5SA expression increased the reporter activity, and mCAR activation enhanced this increase, while CAR activation alone did not induce YAP/TEAD-dependent transcription. TCPOBOP treatment alone also had no effect on the transcription (data not shown). The influence of YAP activation on CAR-dependent transcription was also investigated by reporter gene assays using CAR-responsive element-containing plasmid (Supplementary Figure 1) . The mCAR-dependent increase in reporter activity was enhanced by mYAP-5SA coexpression, while mYAP-5SA expression alone did not affect the activity. These results strongly suggest the presence of crosstalk between CAR and YAP/TEAD in gene transcription.
Influence of mCAR Overexpression on the Proliferation of Mouse Hepatocytes In Vitro
Next, we aimed to reproduce CAR-dependent hepatocyte proliferation in an in vitro system in order to investigate the role of YAP/TEAD signals in CAR-dependent hepatocyte proliferation. In general, mature hepatocytes are arrested at the G0-phase of the cell cycle (Ishiki et al., 1992) , but the cells have the ability to undergo proliferation when they are exposed to certain chemical compounds. Recently, efforts have been made to reproduce the proliferation of mouse primary hepatocyte as observed in vivo using epidermal growth factor, nicotinamide and other factors (Nakamura et al., 1986) . However, no group has completely reproduced hepatocyte proliferation in an in vitro system. As shown in Supplementary Figure 2A , TCPOBOP treatment slightly increased cell numbers (approximately 1.2-fold) of mouse primary hepatocytes for 72 h. Under this experimental condition, Car mRNA levels were drastically decreased by approximately 95% at 24 h after seeding compared with that at 4 h (Supplementary Figure 2B) . Therefore, we suspected that the lack of the proliferative capacity of primary hepatocytes is, at least in part, due to the limited expression of CAR.
We therefore investigated the influence of mCAR overexpression on the proliferation in mouse primary hepatocytes. When AML12 cells, immortalized normal mouse hepatocytes, were infected with an adenovirus expressing V5-tagged mCAR (Ad-mCAR-V5), the mCAR-V5 protein levels were robustly increased in a multiplicity of infection (MOI)-dependent manner (Supplementary Figure 2C) . We therefore infected mouse primary hepatocytes with Ad-mCAR-V5 ( Figure 4A ). As a result, MOI-dependent cell growth was observed ( Figure 4B ), and TCPOBOP treatment enhanced this cell proliferation ( Figure 4C ). The mRNA levels of Cyp2c55, an mCAR target gene (Konno et al., 2010) , and those of cell proliferation markers (Ccna2, Ccnb1, Nek2, Mcm2, and Foxm1) were increased by CAR expression and TCPOBOP treatment ( Figure 4D ). Recently, we have reported that the CAR-mediated proliferation of mouse hepatocytes is enhanced by pregnane X receptor (PXR) activation (Shizu et al., 2016) . To confirm whether or not this characteristic is retained in this in vitro system, mouse primary hepatocytes were simultaneously infected with Ad-mCAR-V5 and Ad-mPXR-V5 and cotreated with TCPOBOP and PCN (a mouse PXR activator), and then the cell growth was investigated. As expected, Ad-mPXR-V5 infection alone did not affect the cell number, but co-infection with both adenoviruses increased the cell number much more markedly than single infection with AdmCAR-V5 (Supplementary Figure 2D) , suggesting that both CAR and PXR are functional in the adenovirus-mediated system. We next investigated whether or not CAR overexpression could also induce the cell proliferation of AML12 cells. In AML12 cells, TCPOBOP treatment alone did not induce cell proliferation probably because of the low CAR expression (Supplementary Figure 3) . With adenovirus infection ( Figure 5A ), mCAR expression-and TCPOBOP-dependent cell proliferation as well as increases in the mRNA levels of Ccna2, Ccnb1, Mcm2, and Foxm1 were also observed in AML12 cells (Figs. 5B-D) .
These results strongly suggest that CAR overexpression enables us to monitor the proliferation of mouse hepatocytes in vitro. Thus, these systems can be used as in vitro models of CAR-mediated hepatocyte proliferation in mouse livers.
The Crosstalk between CAR and Yap in Hepatocyte Proliferation
YAP is well known to regulate cell proliferation through TEAD activation. As shown in Figure 1 , TCPOBOP administration promoted YAP nuclear translocation (i.e., activation) in mouse livers. We therefore anticipated that CAR could crosstalk with the YAP/TEAD signals in hepatocyte proliferation. To test this, we first knocked down the Yap expression in AML12 cells with siRNA and then infected the cells with Ad-mCAR-V5 and treated them with TCPOBOP ( Figure 6A ). Under this condition, the mRNA levels of Yap were decreased by approximately 75% with mYAP-siRNA transfection. YAP protein levels were also decreased with this mYAP-siRNA (data not shown). In the control siRNA-transfected cells, Ad-mCAR-V5 infection and TCPOBOP treatment increased not only the mRNA levels of cell cyclerelated genes, such as Ccna2, Ccnb1, Mcm2, and Foxm1, but also those of YAP target genes, including Ankrd1, Cyr61, and Birc5 ( Figure 6B) . Intriguingly, the CAR-mediated increases were completely blocked or drastically attenuated in Yap knockdown ( Figure 6B) . Furthermore, the cell number was increased by mCAR activation in control siRNA-transfected cells, but again this increase was significantly diminished by Yap knockdown ( Figure 6C ). Consistently, treatment with verteporfin blocked the CAR-dependent cell proliferation in AML12 cells, as indicated by the mRNA levels of cell cycle-associated genes as well as the cell number (Figs. 7A-C) . The CAR activationmediated increases in YAP-target gene mRNA levels were also inhibited by verteporfin treatment (Figure 7B ), suggesting that the increase induced by CAR activation is YAP-dependent. In addition, we found that Yap knockdown and verteporfin treatment had marginal effects on serum-dependent cell growth (Supplementary Figure 4) . These results suggest that the activation of the YAP/TEAD transcriptional complex is crucial for the CAR-dependent proliferation of mouse hepatocytes.
DISCUSSION
In this study, we established in vitro models of CAR-dependent hepatocyte proliferation and identified the crosstalk between Figure 6 . Influence of YAP knockdown on the mCAR-dependent proliferation of AML12 cells. AML12 cells were seeded on 6-or 96-well plates at 1 Â 10 5 or 3.5 Â 10 CAR and YAP/TEAD signals. Most importantly, we demonstrated that mCAR overexpression is able to induce hepatocyte proliferation in vitro, and the inhibition of YAP function almost completely blocks the CAR-dependent hepatocyte proliferation in our in vitro system. Kowalik et al. previously reported that TCPOBOP treatment increased YAP nuclear protein levels in mouse livers (Kowalik et al., 2011) , but the mechanism and its role have been unclear. Our findings thus first demonstrate the critical role of YAP in CAR-dependent hepatocyte proliferation in mice.
In this study, we first examined whether or not CAR could functionally interact with YAP/TEAD signals in hepatocyte proliferation and liver hypertrophy. In the liver of TCPOBOP-treated mice, YAP nuclear localization was observed (Figure 1 ). Co-treatment of mice with the YAP/TEAD inhibitor verteporfin prevented TCPOBOP-induced liver hypertrophy and tended to Figure 7 . Influence of verteporfin treatment on the mCAR-dependent proliferation of AML12 cells. AML12 cells were seeded as in Figure 5 and treated as indicated in the scheme in (A). Verteporfin was used at a final concentration of 0.24 mM. B, Seventy-two hours after cell seeding, total RNA was collected and subjected to qRT-PCR. C, One hundred and twenty hours after seeding, the cell number was assessed by a WST-8 assay. Values are the mean 6 SD (n ¼ 4). Columns not sharing a common letter (a, b) differ significantly from each other (p .05; Tukey-Kramer test).
attenuate TCPOBOP-induced increases in the mRNA levels of YAP target genes as well as those associated with hepatocyte proliferation (Figure 2 ). These results suggest that CAR activation induces YAP activation and enhances the YAP-dependent gene expressions, and that the activation of YAP/TEAD complex plays a key role in the CAR-dependent cell proliferation in mouse livers.
We aimed to reproduce CAR activation-dependent hepatocyte proliferation in an in vitro system because such a system would be very useful for studying the mechanism underlying CAR-mediated hepatocyte proliferation. Mouse primary hepatocytes are known to maintain various liver functions but are unable to proliferate in vitro upon exposure to chemical stimuli, including phenobarbital. Since the CAR expression was extremely reduced after hepatocyte seeding (Supplementary Figure 2B) , possibly explaining why primary hepatocytes are unable to proliferate in vitro, we overexpressed mCAR in hepatocytes and found that mCAR overexpression with its ligand treatment enables hepatocytes to proliferate in vitro (Figure 4 ). This CAR-dependent hepatocyte proliferation was enhanced by the co-activation of PXR (Supplementary Figure 2D) , which is consistent with our recent findings that PXR activation enhances CAR-and PPARa-mediated hepatocyte proliferation (Shizu et al., 2013) . In addition to primary hepatocytes, CAR activation induced the cell proliferation of immortalized AML12 cells ( Figure 5 ). Taken together, these results strongly suggest that the hepatocyte proliferation observed in our in vitro models is biologically equivalent to that observed in vivo in mice. To our knowledge, no models have convincingly reproduced hepatocyte proliferation in vitro. Therefore, ours are the first in vitro proliferation models of mouse hepatocytes. These models seem to be useful for unraveling the mechanism for hepatocyte proliferation and hepatocarcinogenesis induced by CAR activators, such as phenobarbital.
Using the established models, we detected the crucial role of YAP in the CAR-dependent cell growth. In AML12 cells, both the siRNA-mediated knockdown of YAP and pharmacological inhibition of YAP/TEAD interaction drastically diminished the CARdependent cell growth and increases in the mRNA levels of cell proliferation marker genes (Figs. 6 and 7) . In previous studies, CAR activation increased the expression of Myc, Foxm1, Ccnd1, and other cell proliferation markers, but their expression mechanisms have been unclear (Blanco-Bose et al., 2008; LeddaColumbano et al., 2000; Osabe et al., 2008; Shizu et al., 2013) . The expression of Myc and other cell proliferation marker genes was regulated by activated YAP (Dong et al., 2007) . In addition, YAP, as a transcriptional cofactor with no DNA biding domain, regulates the gene expression through interactions with TEADs and other transcription factors. These facts have raised the possibility of a functional interaction between YAP and CAR. In fact, we observed that CAR enhanced YAP/TEAD-dependent gene transcription in vitro ( Figure 3B) .
Interestingly, we also found that mCAR-dependent gene transcription was enhanced by YAP activation in vitro (Supplementary Figure 1) . Furthermore, in mice, verteporfin cotreatment attenuated not only TCPOBOP-induced liver hypertrophy but also the increase in the mRNA levels of CAR target genes, namely Cyp2b10 and Cyp2c55, induced by TCPOBOP treatment (Figure 2 ). These results suggest that YAP acts as a coactivator for the CAR-mediated CYP gene expressions, further supporting the functional crosstalk between CAR and YAP in the nucleus of hepatocytes.
Among the YAP target genes, Birc5 showed a remarkable response to CAR activation both in vivo and in vitro (Figs. 1, 6 , and 7).
BIRC5 is a member of inhibition of apoptosis family, which is also implicated in the regulation of cell proliferation (Altieri, 2003) . Since a previous report showed that CAR had antiapoptotic effects (Yamamoto et al., 2010) , BIRC5 might be a critical factor for CAR-induced cell proliferation and anti-apoptosis. Recently, Ganzenberg et al. reported that CAR-mediated liver hypertrophy and hepatocyte proliferation occur through the Wnt/b-catenin pathway (Ganzenberg et al., 2013) , which is known to have crosstalk with the YAP/Hippo pathway (Kim et al., 2016; Morris et al., 2016) . Although Hippo pathway activation suppresses Wnt/b-catenin pathway activation (Heallen et al., 2011) , Wnt/b-catenin pathway activation promotes YAP nuclear translocation and YAP/TEAD-dependent gene expression through the interaction between b-catenin and YAP, and b-catenin regulates Birc5 transcription (Azzolin et al., 2014; Imajo et al., 2012; Kim et al., 2003) . These facts imply the importance of the CAR-Wnt/ b-catenin-YAP axis in CAR-dependent cell proliferation.
Our present findings strongly suggest that YAP plays a crucial role in the CAR-mediated proliferation of mouse hepatocytes. We also showed that serum-induced hepatocyte proliferation was YAP-independent in our models (Supplementary Figure 4) . Yu et al. (2012) reported that growth factors including epidermal growth factor had no effect on YAP activation. Taken together, these present and previous findings suggest that the hepatocyte proliferation mediated by CAR and that mediated by growth factors are managed, at least in part, through different mechanisms. This may facilitate our understanding of CARmediated hepatocyte proliferation.
Several compounds, including phenobarbital, activate both human and rodent CAR. However, whether or not CAR activation in humans induces hepatocyte proliferation and hepatocarcinogenesis as in rodents has not been confirmed. Future studies on the functional interactions between YAP and CAR may provide a clue to these species differences. Furthermore, studies thus far have mainly focused on gene regulation by CAR through its direct binding to gene promoters, and only a few reports have focused on its crosstalk with other transcription factors and signal transduction pathways. YAP is reported to be phosphorylated by JNK, ERK and AKT, and these kinases are involved in autophagy, tissue differentiation and other biological reactions (Tomlinson et al., 2010; Van Der Heide et al., 2004) . Clarifying the relationship between them and CAR from the view point of YAP activation may reveal the roles of CAR in various biological reactions as well as chemical carcinogenesis. We believe that our present findings are fundamental to those future investigations.
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